Article

Immune modulation by silencing IL-12 production in dendritic cells using small interfering RNA

Department of Medicine, Division of Rheumatology, University of Western Ontario, London, Ontario, Canada.
The Journal of Immunology (Impact Factor: 5.36). 08/2003; 171(2):691-6. DOI: 10.4049/jimmunol.171.2.691
Source: PubMed

ABSTRACT RNA interference is a mechanism of posttranscriptional gene silencing that functions in most eukaryotic cells, including human and mouse. Specific gene silencing is mediated by short strands of duplex RNA of approximately 21 nt in length (termed small interfering RNA or siRNA) that target the cognate mRNA sequence for degradation. We demonstrate here that RNAi can be used for immune modulation by targeting dendritic cell (DC) gene expression. Transfection of DC with siRNA specific for the IL-12 p35 gene resulted in potent suppression of gene expression and blockade of bioactive IL-12 p70 production without affecting unrelated genes or cellular viability. Inhibition of IL-12 was associated with increased IL-10 production, which endowed the DC with the ability to stimulate production of Th2 cytokines from allogenic T cells in vitro. Furthermore, siRNA-silenced DC lacking IL-12 production were poor allostimulators in MLR. IL-12-silenced and KLH-pulsed DC polarized the immune response toward a Th2 cytokine profile in an Ag-specific manner. These data are the first to demonstrate that RNA interference is a potent and specific tool for modulating DC-mediated immune responses.

Download full-text

Full-text

Available from: Thomas E Ichim, Oct 01, 2014
0 Followers
 · 
98 Views
  • Source
    • "They have been also used to create " knockdown " tissues in mice, since they can be expressed in certain adult stem cells, notably hematopoietic stem cells. Moreover, retroviruses for RNAi could potentially be applied for ex vivo cellular manipulations, including those of dendritic cells for the modulation of immune responses [212]. However, the use of these vectors may be associated with a risk of insertional mutagenesis and should be carefully evaluated [213]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The specific targeting and inactivation of gene expression represents nowadays the goal of the mainstream basic and applied biomedical research. Both researchers and pharmaceutical companies, taking advantage of the vast amount of genomic data, have been focusing on effective endogenous mechanisms of the cell that can be used against abnormal gene expression. In this context, RNA represents a key molecule that serves both as tool and target for deploying molecular strategies based on the suppression of genes of interest. The main RNA-mediated therapeutic methodologies, deriving from studies on catalytic activity of ribozymes, blockage of mRNA translation and the recently identified RNA interference, will be discussed in an effort to understand the utilities of RNA as a central molecule during gene expression.
    Current topics in medicinal chemistry 02/2006; 6(16):1737-58. DOI:10.2174/156802606778194253 · 3.45 Impact Factor
  • Source
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Protease-activated receptors (PARs) are activated by proteolytic cleavage of their extracellular domain, unmasking a new N-terminus acting as a tethered ligand. PAR1 and PAR3 were investigated at the promoter level. Using DNase I footprinting, binding of the AP-1 transcription factor to the PAR1 promoter was localized. This indicates that NF-kB does not activate the promoter directly, but interacts with AP-1, which then occupies its binding site on the promoter. The role of PARs in human monocyte-derived dendritic cells was further investigated. Three different inducers of dendritic cell maturation were used, LPS, TNF-a, and CD40L. LPS maturation elicited enhanced expression of PAR1 and PAR3, while the two other stimuli slightly up-regulated PAR1 and PAR3 expression. PAR4 expression remained undetectable in all three maturation types. Thrombin stimulation of LPS-matured dendritic cells resulted in a chemotactic response. The peptide agonists, PAR1-AP and PAR3-AP, produced thrombin-like effects on chemotaxis. PAR1 and PAR3 antibodies were effective in blocking the thrombin responses. Subsequently we investigated the thrombin signalling pathway in dendritic cells, and detected that thrombin activates the Rho-kinase (ROCK), which phosphorylates the myosin light chain (MLC) 2. Thrombin stimulation also induced an increase in actin polymerisation. Both of these events are important for the cell migration. Finally, the treatment of dendritic cells with the specific pharmacological inhibitor of ROCK (Y-27632), completely abolished the MLC phosphorylation, suggesting that thrombin stimulates the dendritic cell migration through Rho/ROCK pathway. The major finding of this work is that dendritic cells are activated by thrombin. Since both thrombin and dendritic cells are present in atherosclerotic plaques, targeting this mechanism in the endothelium could prevent plaque destabilisation and become a novel therapeutic strategy for the treatment of atherosclerosis.
Show more